Search research articles

Search research articles

Related Experiment Videos

Tezacitabine Hoechst Marion Roussel.

¹Georgia Institute of Technology, School of Chemistry and Biochemistry, Boggs Building, Atlanta, GA 30332-0400, USA. seley@chem-mail.chemistry.gatech.edu

Current Opinion in Investigational Drugs (London, England : 2000)

|March 16, 2001

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

CoFactor (Biokeys Pharmaceuticals).

IDrugs : the investigational drugs journal·2005

Same author

Selective transport of a new class of purine antimetabolites by the protozoan parasite Trypanosoma brucei.

Nucleosides, nucleotides & nucleic acids·2004

Same author

Inhibition of measles virus replication by 5'-nor carbocyclic adenosine analogues.

Antiviral chemistry & chemotherapy·2002

Same author

"Fleximers". Design and synthesis of two novel split nucleosides.

Organic letters·2001

Same author

Synthesis and antitumor activity of thieno-separated tricyclic purines.

Journal of medicinal chemistry·2000

Same author

Carbocyclic 5'-noruridine.

Nucleosides, nucleotides & nucleic acids·2000

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Tezacitabine, a deoxycytidine analog, is an irreversible ribonucleotide reductase inhibitor. While showing promise in early trials for solid tumors, it did not demonstrate significant standalone activity in non-small cell lung cancer.

Area of Science:

Oncology
Pharmacology
Drug Development

Background:

Tezacitabine (MDL-101731, KW-2331, FMdC) is an antimetabolite deoxycytidine analog.
It functions as an irreversible ribonucleotide reductase inhibitor and DNA chain terminator.
Developed by Hoechst Marion Roussel, it is under development by Matrix and Kyowa for solid tumors.

Purpose of the Study:

To evaluate tezacitabine as a potential treatment for solid tumors, including colorectal and hematological cancers.
To assess the efficacy and tolerability of tezacitabine in various clinical trial settings.
To explore tezacitabine's potential in combination therapies for advanced cancers.

Main Methods:

Phase I and II clinical trials were conducted to assess tezacitabine's safety and efficacy.

Related Experiment Videos

Dose-escalation studies involved intravenous infusions at varying schedules and doses (16 to 630 mg/m2).

Combination studies with cisplatin and 5-FU were initiated.

Main Results:

Phase I trials in 70 patients indicated tezacitabine was well tolerated.
Indications of efficacy were observed in patients with various advanced solid tumors.
A Phase II trial in non-small cell lung cancer showed no meaningful standalone activity at the tested dose and regimen.

Conclusions:

Tezacitabine is a well-tolerated agent with observed efficacy signals in advanced solid tumors.
Further investigation is warranted, particularly in combination therapies.
Standalone efficacy in non-small cell lung cancer was not demonstrated in initial Phase II evaluations.